The Recent Development of α7 Nicotinic Acetylcholine Receptor (nAChR) Ligands as Therapeutic Candidates for the Treatment of Central Nervous System (CNS) Diseases

Author(s): Corinne Beinat, Samuel D. Banister, Marco Herrera, Michael Kassiou

Journal Name: Current Pharmaceutical Design

Volume 22 , Issue 14 , 2016

Become EABM
Become Reviewer
Call for Editor


Homomeric α7 nicotinic acetylcholine receptors (nAChRs) are implicated in the regulation of cognitive processes such as memory and attention and have potential as therapeutic targets for the treatment of the cognitive deficits associated with schizophrenia. Though numerous α7 nAChR agonists have been developed, and several have progressed to clinical trials, these are derived from few common chemotypes. Consequently, many of these α7 nAChR clinical candidates share unfavorable side-effect profile. SEN12333 represents a novel chemotype for the development of α7 nAChR agonists, and exploration of this scaffold has produced structurally diverse ligands with promising pharmacological properties. This review will summarize structure-affinity and -activity relationships surrounding analogs of SEN12333.

Keywords: Nicotinic receptors, schizophrenia, Alzheimer’s disease, SEN12333.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 27 April, 2016
Page: [2134 - 2151]
Pages: 18
DOI: 10.2174/1381612822666160127114125
Price: $65

Article Metrics

PDF: 57